# Lan Huang

> Lan Huang is a chemist turned biotech entrepreneur and the Co-Founder, Chairman and CEO of SEED Therapeutics, a New York clinical-stage company designing molecular glues that direct the cell's own disposal machinery to break down disease-driving proteins once considered undruggable. She earlier founded BeyondSpring Pharmaceuticals and took it public on NASDAQ. A UC Berkeley PhD who solved an early E3 ubiquitin ligase structure, she built SEED around targeted protein degradation with collaborators including Nobel laureate Avram Hershko, and secured partnerships with Eli Lilly and Eisai.

- **Role:** Co-Founder, Chairman & CEO at SEED Therapeutics
- **Organizations:** SEED Therapeutics, BeyondSpring Pharmaceuticals, Paramax International, WuXi MTLH Biotechnology
- **Education:** PhD in Chemistry, University of California, Berkeley, Postdoctoral training (ubiquitin ligase / cancer signaling), Memorial Sloan Kettering Cancer Center
- **Known for:** Co-founded and leads SEED Therapeutics, a clinical-stage targeted protein degradation company, Founded BeyondSpring Pharmaceuticals and took it public on NASDAQ (BYSI), Solved an early structure of an E2-E3 ubiquitin ligase complex involved in p53 degradation (published in Science)

## Career timeline

- **1998-2002** — Postdoctoral training at Memorial Sloan Kettering Cancer Center, focused on E3 ubiquitin ligases and p53 degradation
- **2007** — Co-founded WuXi MTLH Biotechnology in China
- **2010** — WuXi MTLH cancer peptide drug acquired by Shanghai Pharmaceutical Group
- **2011** — Paramax International (clinical CRO she co-founded) sold to RPS, then to Warburg Pincus
- **2010s** — Founded BeyondSpring Pharmaceuticals; later took it public on NASDAQ (BYSI) and advanced plinabulin to NDA filing in the US and China
- **2020** — Co-founded SEED Therapeutics; signed research collaboration and license agreement with Eli Lilly worth up to ~$800M
- **2025** — SEED Therapeutics named a finalist for the 2025 Prix Galien USA Best Start-Up Award; closed Series A financing

## Achievements

- Co-founded and leads SEED Therapeutics, a clinical-stage targeted protein degradation company
- Founded BeyondSpring Pharmaceuticals and took it public on NASDAQ (BYSI)
- Solved an early structure of an E2-E3 ubiquitin ligase complex involved in p53 degradation (published in Science)
- Negotiated a research and license collaboration with Eli Lilly worth up to roughly $800 million, plus a partnership with Eisai
- Built the RITE3 molecular glue discovery platform targeting the undruggable proteome
- Won the Graduating PhD Woman Award from Soroptimist International at UC Berkeley
- Holds patents for biotech products in oncology and dermatology

## Latest updates

- **2025-08** — SEED Therapeutics named a finalist for the 2025 Prix Galien USA Best Start-Up Award.
- **2025-08** — SEED Therapeutics closed a Series A financing round (latest funding ~$6M tranche; total funding reported around $65M).

## Links

- Website: https://seedtherapeutics.com
- LinkedIn: http://www.linkedin.com/in/lan-huang-phd-5104933
- Twitter/X: https://twitter.com/seedtx

---

Profile page: https://yespress.io/lan-huang
Published by YesPress — https://yespress.io
Last updated: 2026-07-15